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Abstract
The natural history of chronic obstructive pulmonary disease (COPD) is still not well under-
stood. Traditionally believed to be a self-inflicted disease by smoking, now we know that not
all smokers develop COPD, that other inhaled pollutants different from cigarette smoke can
also cause it, and that abnormal lung development can also lead to COPD in adulthood.
Likewise, the inflammatory response that characterizes COPD varies significantly between
patients, and not all of them perceive symptoms (mostly breathlessness) similarly. To inves-
tigate the variability and determinants of different “individual natural histories” of COPD, we
developed a theoretical, multi-stage, computational model of COPD (EASI) that integrates
dynamically and represents graphically the relationships between exposure (E) to inhaled
particles and gases (smoking), the biological activity (inflammatory response) of the disease
(A), the severity (S) of airflow limitation (FEV1) and the impact (I) of the disease (breathless-
ness) in different clinical scenarios. EASI shows that the relationships between E, A, S and I
vary markedly within individuals (through life) and between individuals (at the same age). It
also helps to delineate some potentially relevant, but often overlooked concepts, such as
disease progression, susceptibility to COPD and issues related to symptom perception.
In conclusion, EASI is an initial conceptual model to interpret the longitudinal and cross-
sectional relationships between E, A, S and I in different clinical scenarios. Currently, it does
not have any direct clinical application, thus it requires experimental validation and further
mathematical development. However, it has the potential to open novel research and teach-
ing alternatives.
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Introduction
The natural history of chronic obstructive pulmonary disease (COPD) is still not well
understood. Traditionally believed to be a self-inflicted disease by smoking [1], now it is
well established that not all smokers develop the disease [2], that other inhaled pollutants
different from cigarette smoke can also cause COPD [3], and that early-life events can jeop-
ardize lung development and lead to COPD in adulthood [4–6]. Likewise, albeit inflamma-
tion is considered a key pathogenic player [7], the type and severity of the inflammatory
response (the biological activity of the disease) varies significantly between patients [8, 9].
Finally, the clinical impact of the disease (how the patient perceives the symptoms origi-
nated by the disease, mostly breathlessness) also varies across patients with similar lung
function impairment [10, 11].
Computational models can help to understand complex biological problems by offering
a theoretical framework where to explore the relationships amongst different variables
[12]. They have, therefore, the potential to generate novel hypotheses that can be later
tested experimentally [12, 13]. Here, we hypothesize that the natural history of COPD is
the end-result of a complex multi-stage process (environmental exposures, biological
response, lung structure and function deterioration and symptom perception), and that
each of these stages exhibits large individual variability that result in different natural his-
tory trajectories. As a first attempt to explore this hypothesis, we developed an individual-
ized, multi-stage computational model of COPD (named EASI) that explores, integrates
and displays graphically the dynamic relationships in a given individual between Exposure
(smoking), Activity (Inflammation), Severity (as assessed by the expired volume of gas in
the first second of a forced spirometry maneuver—FEV1) and Impact of the disease (dys-
pnea). We explicitly acknowledge that, at this stage of development, EASI cannot be used
to predict the course of the disease in a given individual, nor the response to any therapeu-
tic intervention. By contrast, EASI is envisaged as a theoretical, conceptual computational
model that begins to explore the relationships between E, A, S and I in different clinical sce-
narios to facilitate the design of appropriate field studies that can confirm or dispute the
predictions of the model [13].
Methods
As shown in Fig 1, EASI has 4 stage modules (Exposure, Activity, Severity and Impact), each of
them defined by 4 dynamic variables (E(t), A(t), S(t), I(t)) and 15 input parameters (Table 1)
which were based on published data when available [6, 14, 15] or, in its absence, clinical expe-
rience. The mathematical assumptions and specific differential equations used in each module
are detailed in the S2 File. In brief, E(t)models smoking related parameters as the product of
two sigmoid (logistic) functions of time (for the initiation and quitting of smoking, respec-
tively), whereas A(t), S(t) and I(t) are modeled using first-order linear ordinary differential
equations that depend on one another in a hierarchical, feed forward way (A depends on E, S
on A, and I on S). These differential equations were integrated using an Euler method with
time step Δt = 0.2 years. The model was written as an interactive spread sheet using the freely-
available package LibreOffice (http://www.libreoffice.org). This fully workable spread sheet is
available in the S1 File, licensed under a Creative Commons Attribution 4.0 International
License. EASI parameters were calibrated in silico using a Matlab custom code (The Math-
works, Inc.) by comparison with available FEV1 population data, both for smoking and non-
smoking populations, as detailed in the S2 File.
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Results
Longitudinal, age-related, multi-stage dynamics in different clinical
scenarios
Fig 1 presents the graphic EASI representation of a theoretical (but frequent) case of a suscepti-
ble, continuous long-life smoker who develops COPD in adult life (Table 1 presents the 15 spe-
cific input parameters used to compute this particular scenario). Of note, this theoretical
individual: (1) starts to smoke at the age of 15 yrs., achieves a maximal exposure of 1.5 pack-yr.
within 5 yrs., and never quit or modify the daily dose of smoking; (Fig 1, top left panel); (2) has
normal lung development, as shown by an FEV1 at the age of 20 years of 100% ref. [16] (Fig 1,
heat map in bottom central panel); and, (3) begins to perceive dyspnea from a value of FEV1
<80% ref (Fig 1, bottom right panel). The results of the relationships between the E, A, S and I
modules are displayed in two age-related panels (Fig 1, central panels) that summarize the
“natural history” of COPD in this particular individual. The upper central panel shows that the
onset and persistence of smoking (blue line) induced a rapid and sustained inflammatory
activity (red line) that is associated with a progressive loss of FEV1 (cyan line, right Y axis),
starting at the age of 30 years approximately, and reaching a FEV1 45% of reference at the age
of 80 (see heat-map in bottom central panel), with a progressive perception of symptoms
(green line) from the fifth or sixth decade of age (reaching 68% of maximal impact I at 80 years
of age).
Fig 2 compares this theoretical scenario (Panel 1) with 5 other potential “natural histo-
ries” (Panels 2–6). Table 1 details the specific parameter values used to simulate each of
them. Panel 2 assumes that the same individual shown in Panel 1 now quits smoking at the
age of 45 yrs. (see S4 Fig for details). Note that, now, the blue (E) and red (A) lines fall to
Fig 1. Graphic display of the EASI model structured around four modules (Exposure (top left),Activity (bottom left), Severity (top right), Impact
(bottom right)), each of which presents the parameter values used to calculate it, and the relevant steady-state activation functions linking
inputs from previousmodule (X axis) to module outputs (Y axis). In E, the black solid line indicates daily smoking exposure (pack/day; left Y axis) as a
function of age (X axis), whereas the dashed line corresponds to the cumulative smoking exposure (pack-years, right Y axis) of that particular individual.
The EASI model also includes two central panels. The top one presents a longitudinal summary of the age-related trajectories of Exposure (blue line),
Activity (red line), FEV1 (cyan line; right Y panel) and Symptoms (green line). The bottom (centre) panel presents a heat-map of these same four variables
by decade. This particular example illustrates the EASI relationships for a susceptible continuous smoker (Table 1 details the parameter values used here).
For further explanations, see text.
https://doi.org/10.1371/journal.pone.0185502.g001
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zero as a consequence of smoking cessation and inflammation remission, whereas the S
(cyan line; FEV1) and I (green line) slopes become less steep. Panel 3, presents a smoker
quitting smoking later in life (at 65 yrs. (see S5 Fig for details) and shows that, in keeping
with previously published data [2], improvements of S and I are less marked after quitting at
older age (compare Panels 2 and 3). Panel 4 is identical to Panel 2 (see Table 1 and S6 Fig for
details), except that, as suggested in the literature [17], EASI now assumes that despite quit-
ting smoking, inflammatory activation persists at 40% of the maximal value (note that the
red line now plateaus, and S and I continue to deteriorate). Panel 5 (see S7 Fig for details) is
similar to Panel 1, except that now the model assumes that lung development was impaired
in early life, so maximal lung function at 20 years of age was 75% of maximal normal func-
tion (see % FEV1 values in the corresponding heat map). Finally, Panel 6 (see S8 Fig for
details) is also similar to Panel 1, but now the patient perceives dyspnea poorly, as illustrated
by the comparison of the green line (I) in Panels 6 vs.1.
Cross-sectional patterns of trajectories
In clinical practice, patients generally consult when they perceive symptoms in late adulthood.
At that time, life-long longitudinal information is lacking almost invariably, so practicing
Table 1. Input parameters (n = 15) used to generate the six different clinical scenarios analyzed. Bold italic figures highlight the changes introduced in




quitter at 45 years
(3) Susceptible








1. Age of smoking
onset, yrs.
15 15 15 15 15 15
2. Maximal exposure
(packs/day)
1.5 1.5 1.5 1.5 1.5 1.5
3. Time to max.
exposure, yrs.
5 5 5 5 5 5
4. Age of quitting, yrs. Non-quitter 45 65 45 Non-quitter Non-quitter
5. Time to complete
quitting, yrs.
- 1 1 1 - -
6. Activity trigger,
pack/day
0.3 0.3 0.3 0.3 0.3 0.3
7. Slope to maximal
activity
2 2 2 2 2 2
8. Persistence after
quitting, % activity
Non-quitter 0 0 40 Non-quitter Non-quitter
9. Normal rate of
FEV1 decline, ml/yrs.
30 30 30 30 30 30
10. Activity trigger, %
activity
10 10 10 10 10 10
11. Slope to maximal
severity
2 2 2 2 2 2
12. Maximal rate of
FEV1 decline, ml/yrs.
100 100 100 100 100 100
13. FEV1 at 20 yrs. of
age, liters
4 (100% ref.) 4 (100% ref.) 4 (100% ref.) 4 (100% ref.) 3.0 (75% ref) 4 (100%
ref.)
14. Impact trigger, %
reference FEV1
80 80 80 80 80 50
15. Slope to max.
Impact
2 2 2 2 2 2
https://doi.org/10.1371/journal.pone.0185502.t001
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physicians need to integrate available cross-sectional information (basically E, S and I, since A
is rarely, if ever, measured). It was therefore of interest to compare the cross-sectional pattern
(by decade of age) of the six different scenarios described in Fig 2. Their visual comparison
(see heat-maps in Fig 2) illustrates that the pattern of E, A, S and I relationships varies greatly
within each clinical scenario at different ages (e.g. 30 vs. 60 yrs.), as well as between clinical sce-
narios at the same age (e.g., 60 years, when most COPD patients are diagnosed in the clinic).
Finally, we modeled (see Table 2 for parameter values) four different hypothetical patients
consulting at the age of 50 years with a similar level of symptoms (Fig 3, arrow) but remarkably
different individual life-time E, A, S and I trajectories. Fig 3 includes a non-smoker individual
(Patient 4) with low lung function at early age (Table 2) who, according to S only would be
likely to be diagnosed of COPD later in life [6].
Discussion
To our knowledge this is the first computational model to simulate the individual variability of
COPD “natural histories” [13]. EASI shows that, in contrast to the current idealized one-size-
Fig 2. Comparison of six different, potentially relevant clinical scenarios. Panel 1, Susceptible continuous smoker (same as Fig 1); Panel 2,
Susceptible quitter at 45 years of age; Panel 3, Susceptible quitter at 65 years of age; Panel 4, Persistent inflammation after quitting; Panel 5, Abnormal
lung development; and, Panel 6, Poor perceiver. In each of these five different scenarios, top panels present a longitudinal summary of age-related
trajectories of Exposure (blue line), Activity (red line), Severity (FEV1, cyan line) and perceived impact of the disease by the patient (green line), whereas
bottom panels show the corresponding heat-maps by decade. Table 1 details the specific parameter values to eachmodule used to generate each of
these five scenarios, and Fig 1 and S4–S7 Figs displayed each of them graphically in detail. For further explanations, see text.
https://doi.org/10.1371/journal.pone.0185502.g002
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fits-all nature of COPD paradigms, there can be a large degree of individual variability through
time that is often difficult to dissect based on cross-sectional pattern analysis only. Further, it
highlights some, potentially relevant but often overlooked, observations related to the patho-
genesis of the disease, as discussed below. Yet, it is important to reiterate here that EASI does
not pretend to predict the course of the disease in any given patient, nor the response to any
therapeutic intervention, in current clinical practice, albeit we recognize that it may eventually
have such capacity when appropriately validated and developed.
Table 2. Parameter values used to generate the EASI relationships presented in the four different hypothetical patients shown in Fig 3.
Patient 1 Patient 2 Patient 3 Patient 4
Exposure Module
1. Age of smoking onset, yrs. 15 16 17 Non smoker
2. Maximal exposure (packs/day) 3 2 1.5 Non smoker
3. Time to max. exposure, yrs. 1 2.5 2 Non smoker
4. Age of quitting, yrs. 40 45 Non-quitter Non smoker
5. Time to complete quitting, yrs. 1 1 Non-quitter Non smoker
Activity Module
6. Activity trigger, pack/day 0.3 0.1 0.1 0.35
7. Slope to maximal activity 2 3.5 3.5 2
8. Persistence after quitting, % Activity 25 20 Non-quitter Non smoker
Severity Module
9. Normal rate of FEV1 decline, ml/yrs. 12 35 20 20
10. Activity trigger, % epithelial apoptosis 20 10 30 20
11. Slope to maximal severity 2 2.5 1 1
12. Maximal rate of FEV1 decline, ml/yrs. 75 90 75 60
13. FEV1 at 20 yrs. of age, liters 3 4 4.5 2.8
Impact Module
14. Impact trigger, % reference FEV1 90 85 115 85
15. Slope to max. Impact 1 3 2 2
https://doi.org/10.1371/journal.pone.0185502.t002
Fig 3. Age-related Exposure, Activity, Severity and Impact trajectories of four hypothetical patients.
Arrow (bottom right panel) highlights that all four of them had the same I at 50 years of age (when they consult
with the physician). Yet, their E, A, and S trajectories are quite different. Note that one patient (#4) is a never-
smoker individual with low lung function at early age, whomay be diagnosed of COPD later in life (60 years).
For further explanations, see text.
https://doi.org/10.1371/journal.pone.0185502.g003
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Variability of COPD trajectories (i.e., different “natural histories”)
EASI displays the variability and sensitivity to changes of different individual COPD trajecto-
ries by showing that the variation of a single parameter (Fig 2) can change them markedly.
Needless to say that this is a direct consequence of the way EASI was built, having one module
feeding the necessary information to the next one (feed-forward). This kind of relationship is
likely to occur also in real life, but the situation in vivo is much more complex and includes the
possibility of feed-back, redundancy and a range of potential adaptations [12] that are not con-
sidered in the current version of EASI. For example, patients can adapt their daily life activities
to minimize symptoms (i.e., I) when airflow limitation (i.e., S) is severe. Likewise, rehabilita-
tion can have beneficial effects on I and, perhaps on A, without changing S. EASI can be scaled
in the future to accommodate all these potential modifiers and others, such as exacerbations of
the disease [18]. In this context, it is noteworthy that the single change with the greatest effect
on lung function later in life was poor lung function in early adulthood (Fig 2), in line with sev-
eral recent observations [5, 6, 19].
Likewise, EASI also shows that the relationships between E, A, S and I not only vary mark-
edly longitudinally (different scenarios through life) but also cross-sectionally (same scenario
across different ages) (Fig 2). In fact, four different hypothetical patients can present in this
“virtual clinic” with the same I (i.e., symptoms) after having had very different longitudinal tra-
jectories (Fig 3). In essence, this highlights the need of longitudinal studies in well character-
ized cohorts of patients to understand in vivo these different trajectories and, in turn, confirm
(or refute) the initial and simple EASI model presented here.
Disease progression
COPD progression is often assessed by the rate of FEV1 decline [1] but recent evidence has
demonstrated that only a proportion of patients have enhanced FEV1 decline [5, 6]. The EASI
model goes further and indicates that (Fig 2) disease progression in COPD can either indicate
that the disease continues to be biologically “active” (A), with or without continuous exposure
(E), that it has become more “severe” (S) and/or that it has a greater “impact” on the patient
(I). These different disease components require careful and independent consideration when
assessing “disease progression” in COPD.
Susceptibility to COPD
It is well established that not all smokers develop COPD [1, 2], probably because different
genetic backgrounds [20]. Our analysis suggests that this assumption is likely to be much more
complex since differences in “susceptibility” may occur for each of the relevant disease stages.
For instance, the relationship between E (i.e. smoking) and S (i.e. FEV1) is modulated by A, so
it is possible that some individuals may be highly susceptible in terms of mounting an inflam-
matory response that does not translate into clinical disease because their repair mechanisms
prevent lung function deterioration. Such individuals would have been traditionally consid-
ered a “resistant” smoker despite being highly “susceptible” to the biological effects (A) of
smoking. This will have to be considered in future studies of COPD “susceptibility”.
Symptom perception
The clinical impact of any disease, including COPD, depends on how physiologic perturbations
are perceived by the individual, and howmuch these perturbations modify the activities of daily
living [21, 22]. In COPD, it has been generally assumed that mild disease (as assessed by the
FEV1 value) has a minor impact on the patient, whereas the impact is much greater in severe
The EASI computational model of COPD
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disease [23]. Yet, recent evidence has revealed a more complex picture, since the relationship
between the severity of airflow limitation and the level of symptoms reported is poor, and indi-
vidual variability is enormous [10, 24, 25]. All in all, these observations suggest that there may be
poor symptom perceivers among patients with COPD [11], as it is well described in asthma [26,
27]. In fact, EASI predicts that different patients with a similar level of symptoms (I) at a given
age might have had and will continue to have very different E,A, S and I trajectories (Fig 3).
Limitations and opportunities
Currently, EASI has several important limitations: (1) it is an oversimplification of the natural
history of COPD and, for the most part, it lacks experimental validation; (2) it includes only
four modules and accounts deterministically for their sequential relationships. Each of these
modules is susceptible to accommodate other potentially relevant parameters, such as other
environmental factors (e.g. occupational exposures or diet), and future EASI iterations could
also include other COPD characteristics that can influence the natural history of COPD too,
such as the frequency and severity of COPD exacerbations and/or the occurrence of comorbid-
ities; (3) the sequential relationships between modules in EASI do not include effect modifiers
of module-to-module relationships, such as genetic variants or epigenetic modifications,
whose interactions with exposures are likely to influence the individual trajectories of COPD.
As a disclaimer, though, the precise genes involved in the pathogenesis of COPD at different
time points are unclear, so this first version of EASI considers the genetic background of the
individual as a whole. EASI, however, does indeed consider the possibility of modifying lung
function achieved at early adulthood [6, 19]; (4) EASI modeled A pragmatically, without detail-
ing any specific innate and/or acquired mechanism involved [17], because the dynamic inter-
actions of these mechanisms are mostly unknown [28–30]; (5) S was modeled on the basis of
FEV1 only, despite that it is now well established that COPD can associate multiple pulmonary
and extra-pulmonary co-morbidities that can contribute to S independently [31]; and, (6) the
sequential relationships between modules could also be influenced by the effects of drugs used
to treat COPD, such as those of inhaled bronchodilators (potentially modifying S) or cortico-
steroids (potentially modifying A), so future evolutions of the model can include them. No
doubt, therefore, EASI requires experimental validation and refinement through an iterative
research strategy that combines experimental and modeling data.
Yet, EASI also opens some opportunities: (1) it is a first step forward towards the computa-
tional modeling (hence better understanding [12, 32, 33]) of the variable “natural histories”
that can occur in different COPD patients; and, (2) by doing so, it can open novel approaches
for research, teaching and, eventually, practice (precision medicine [34]) of COPD.
Conclusion
EASI is a conceptual, individualized, multi-stage, first-pass, computational model that allows
the investigation of the individual relationships between E, A, S and I and, as a result, a better
understanding of the complexity and heterogeneity of COPD. The current EASI model cannot
be directly applied to clinical practice because it requires validation and further refinement,
but it points toward a potential path towards COPD precision medicine.
Supporting information
S1 Fig. Distribution of values taken by each of the 15model parameters in the in silico simula-
tion of 1,000 randommodels in a smoker population [8]. For non-smoker simulations, parame-
ters in the first row were set to 0 for all 1,000 randommodels. For further explanations, see text.
(TIF)
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S2 Fig. A heterogeneous population of 1,000 models (parameters as per S1 Fig) mimics the
mean value (panel A) and variability (panel B) of FEV1 observed experimentally in non-
smoker males at different ages [7]. FEV1 decay in persistent smoker model simulations
(mean decay across 1,000 models: 50 ml/yr.) is also consistent with experimental data [8]. For
further explanations, see text.
(TIF)
S3 Fig. Distribution of FEV1 at age 60 years in the random 1,000 models (parameters as
shown in S1 Fig) for non-smoker (grey columns) or smoker (white columns) models. Solid
vertical line marks the reference FEV1 value reported in the literature for a male of height 1.75
m, whereas dotted vertical line marks its lower limit of normality [7]. For further explanations,
see text.
(TIF)
S4 Fig. EASI relationships in a susceptible quitter at 45 years of age [12]. For further expla-
nations, see text.
(TIF)
S5 Fig. Same as S4 Fig, but the individual now quits smoking at 65 years of age [12]. For
further explanations, see text.
(TIF)
S6 Fig. EASI relationships in a susceptible quitter (at 45 years of age) in whom inflamma-
tion (i.e. disease activity) persists after quitting [4]. For further explanations, see text.
(TIF)
S7 Fig. EASI relationships in a continuous smoker who had abnormal lung development
early in life [5]. For further explanations, see text.
(TIF)
S8 Fig. EASI relationships in a susceptible continuous smoker with poor perception of dis-
ease impact [13]. For further explanations, see text.
(TIF)
S1 File. Workable spread sheet of the EASI model.
(ODS)
S2 File. On-line supplement.
(DOC)
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